Neuroendocrine tumors of the lung (Lu-NETs) embrace a heterogeneous family of
neoplasms classified into four histological variants, namely typical carcinoid (TC), atypical …

Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important
modality in the therapeutic armamentarium of advanced, metastatic or inoperable …

Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …

Introduction: The combined use of 68gallium (68Ga)-DOTA-peptides and 18fluorine-fluoro-2-
deoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) …

Purpose To evaluate the prognostic value of volumetric parameters calculated from 68 Ga-1,
4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-Thr 3-octreotate (68 Ga …

Progress in the diagnostics and therapy of gastro-entero-pancreatic (GEP) neuroendocrine
neoplasms (NEN), the published results of new randomised clinical trials, and the new …

Neuroendocrine neoplasms (NENs) arise from cells of neuronal and endocrine
differentiation. While they are a rare entity, an increasing proportion of patients with NEN …

Neuroendocrine neoplams (NENs) are mostly relatively indolent malignancies but a
significant number have metastatic disease at diagnosis mainly to the liver. Although in the …

The diagnosis of carcinoma of unknown primary in the head and neck is made when there is
a metastasis but no primary lesion is identified after physical exam and diagnostic CT or MR …

Discordance between histopathologic grading and dual-tracer PET/CT (68Ga-DOTATATE
and 18F-FDG) findings in neuroendocrine tumors (NETs), though not typical, can be …